Abstract

AbstractA large amount of hidden biological information is contained in the human genome, which is not expressed or revealed in the form of proteins; the usual end product form of gene expression. Instead, most of such information is in the form of non-coding RNAs (ncRNAs). ncRNAs correspond to genes that are transcribed, but do not get translated into proteins. This part of the genome was, till recently, considered as ‘junk’. The term ‘junk’ implied lack of any discernible function of these RNA. More than 98% of the human genomic size encompasses these non-coding RNAs. But, recent research has evidently brought out the indispensible contribution of non-coding RNA in controlling and regulating gene expression. ncRNA such as siRNAs and microRNAs have been reported to greatly help in causing post-transcriptional gene silencing (PTGS) in cells through RNA interference (RNAi) pathway. In this work, we have investigated the possibility of using siRNAs and microRNAs to aid in gene silencing of early onset Alzheimer’s disease genes. Alzheimer’s disease specific mutations and their corresponding positions in mRNA have been identified for six genes; Presenilin-1, Presenilin-2, APP (amyloid beta precursor protein), APBB3, BACE-1 and PSENEN. Small interfering RNAs (siRNAs) that can cause PTGS through RNA interference pathway have been designed. RNA analysis has been done to verify complementarity of antisense siRNA sequence with target mRNA sequence. Interaction studies have been done computationally between these antisense siRNA strands and seven Argonaute proteins. From the interaction studies, only one of the seven Argonaute proteins; 1Q8K, was found to have interaction with the siRNAs indicating the importance and uniqueness of this particular protein in RISC (RNA induced silencing complex). The interaction studies have been carried out for the microRNAs also. Out of the 700 mature human microRNAs collected, 394 microRNAs have been identified to show partial complementarity with their target sequence on PSEN-1 mRNA. Of these 394, five microRNAs have shown partial complementarity to early onset Alzheimer’s disease specific mutations in PSEN-1 mRNA. Interaction studies have been done between these microRNAs and Argonaute proteins. Thus, design, characterization and analysis of ncRNAs that contribute to post transcriptional gene silencing of Alzheimer’s disease have been achieved.

Highlights

  • An estimation of ‘United Nation population projection’ reminds that the number of people older than 80 years will become approximately 370 million by the year 2050

  • Antisense strands of small interfering RNAs (siRNAs) of length 20 nucleotides have been designed complementary to nine early onset Alzheimer’s disease specific mutated regions in mRNA encoded by PSEN-1 gene

  • It cannot be consider in post transcriptional gene silencing. 46 functional siRNAs are designed against 72 Alzheimer’s disease specific mutated regions in mRNA encoded by PSEN-1 gene. 53 functional siRNAs have been designed for 81 mutated regions in mRNA encoded by PSEN-1 gene

Read more

Summary

Introduction

An estimation of ‘United Nation population projection’ reminds that the number of people older than 80 years will become approximately 370 million by the year 2050. Current estimation is that about half the strength of people older than 85 years are affected with dementia. This statistics warns that within 50 years, above 100 million people will suffer from dementia. Alzheimer's disease is caused by the deposition of amyloid plaques. Amyloid plaques are produced by the conversion of amyloid precursor protein (APP) into - amyloid (A ). Mutations in genes encoding amyloid precursor protein (APP), presenilin-1 (position in chromosome 14), and presenilin-2 (position in chromosome 1), APBB3, BACE1 and PSENEN causes Alzheimer’s disease. Mutated protein formed leads to Alzheimer’s disease

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call